VYNE reports positive preclinical RA data for pan-BET inhibitor VYN201; on track for H2 2022 Ph1

VYNE Therapeutics Inc.

VYN201 intra-articular injection showed statistically significant inhibition of paw thickening at 1 and 10 mg/kg (p<0.01).
At 1 mg/kg, paw thickness reduced 26.8% vs untreated; at 10 mg/kg, reduced 37.6%.
Arthritis scores at 1 and 10 mg/kg were near normal (0.57 and 0.67), reductions of 76.5% and 79.9%.
VYN201 numerically superior to intra-articular dexamethasone in both endpoints.
Company confirms timeline to initiate first-in-human trial for VYN201 in second half of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.